
    WATSON PHARMACEUTICALS, INC. and Danbury Pharmacal, Inc., Plaintiffs-Appellants, v. Bernard A. SCHWETZ, D.V.M, Ph.D, Acting Principal Deputy Commissioner, U.S. Food and Drug Administration, Defendant-Appellee, and Bristol-Myers Squibb Company, Defendant-Appellee.
    No. 01-1285.
    United States Court of Appeals, Federal Circuit.
    May 20, 2002.
   ON MOTION

ORDER

Bristol-Myers Squibb Co., Watson Pharmaceuticals, Inc. and Danbury Phar-macal, Inc. move jointly to voluntarily dismiss with prejudice. The Acting Principal Deputy Commissioner consents.

Upon consideration thereof,

IT IS ORDERED THAT:

(1) The unopposed motion to dismiss is granted.

(2) The motion to transfer is moot.

(3) All sides shall bear their own costs.  